Combination formulation of aclobifene and prasterone
| Combination of | |
|---|---|
| Acolbifene | Selective estrogen receptor modulator |
| Prasterone | Androgen |
| Clinical data | |
| Trade names | Femivia (tentative) |
| Other names | Prasterone/acolbifene; Acolbifene/DHEA; DHEA/Acolbifene |
| Routes of administration | By mouth |
Acolbifene/prasterone (tentative brand name Femivia) is a combination formulation of acolbifene, a selective estrogen receptor modulator, and prasterone (dehydroepiandrosterone; DHEA), an androgen, estrogen, and neurosteroid, which is under development by Endoceutics for the treatment of vasomotor symptoms (hot flashes) in postmenopausal women.[1] It is intended for use by mouth.[1] As of December 2017, it is in phase III clinical trials for this indication.[1]
See also[edit]
References[edit]
External links[edit]
- Acolbifene/prasterone - AdisInsight
- Pipeline - Endoceutics Archived 2017-10-18 at the Wayback Machine
| ERTooltip Estrogen receptor |
| ||||||
|---|---|---|---|---|---|---|---|
| GPERTooltip G protein-coupled estrogen receptor |
| ||||||